Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06818474
PHASE4
Lanadelumab in Long-term Prophylaxis of Acquired Angioedema
Sponsor: Bernstein Clinical Research Center
View on ClinicalTrials.gov
Summary
use of lanadelumab in patients with acquired angioedema
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
5
Start Date
2024-06-01
Completion Date
2027-12-01
Last Updated
2025-02-25
Healthy Volunteers
No
Conditions
Interventions
BIOLOGICAL
Lanadelumab 300 mg
no other intervention
Locations (1)
Bernstein Clinical Research Center, LLC
Cincinnati, Ohio, United States